LifeStance Health GroupLFST +3.58%56 EV-to-EBITDA is 44.29 as of Jun. 30, 2026. GuruFocus rates LFST with a GF Score™ of 56/100 and a GF Value™ of $8.23 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 505 Healthcare Providers & Services companies, LifeStance Health Group ranks worse than 88.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LifeStance Health Group's enterprise value is $4,353 Mil.
LifeStance Health Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $98 Mil. Therefore, LifeStance Health Group's EV-to-EBITDA for today is 44.29.
The historical rank and industry rank for LifeStance Health Group's EV-to-EBITDA or its related term are showing as below:
LFST'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2200.85 Med: -12.11 Max: 277.48
Current: 44.29
During the past 7 years, the highest EV-to-EBITDA of LifeStance Health Group was 277.48. The lowest was -2200.85. And the median was -12.11.
LFST's EV-to-EBITDA is ranked worse than 88.91% of 505
companies
in the Healthcare Providers & Services industry
Industry Median: 10.97
vs LFST: 44.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
LifeStance Health Group (NAS:LFST) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LifeStance Health Group's PE Ratio (TTM) for today is calculated as:
LifeStance Health Group's share price for today is $10.71.
LifeStance Health Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, LifeStance Health Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeStance Health Group EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LifeStance Health Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LifeStance Health Group's EV-to-EBITDA falls into.
LifeStance Health Group's current Enterprise Value is $4,353 Mil.
LifeStance Health Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeStance Health Group (LFST) has a EV-to-EBITDA of 44.29 as of Jun. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LifeStance Health Group. According to the industry distribution chart, LifeStance Health Group ranks #449 out of 505 companies in the Healthcare Providers & Services industry, placing it in the top 88.9%.
Is LifeStance Health Group's EV-to-EBITDA too high?
LifeStance Health Group's current EV-to-EBITDA is 44.29. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.97. LifeStance Health Group's value of 44.29 is 303.7% above this industry median. Based on the distribution chart, LifeStance Health Group ranks #449 out of 505 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, LifeStance Health Group has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's EV-to-EBITDA compare to CON and BKD?
According to the Healthcare Providers & Services industry distribution chart, LifeStance Health Group ranks #449 out of 505 companies for EV-to-EBITDA. This places LifeStance Health Group in the lower half of its industry. The industry median EV-to-EBITDA is 10.97. LifeStance Health Group's value of 44.29 is 303.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeStance Health Group's current EV-to-EBITDA of 44.29 is 303.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LifeStance Health Group. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeStance Health Group's current EV-to-EBITDA is 44.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.23, compared to a current price of $10.71 — trading 30.1% above its estimated fair value. The current EV-to-EBITDA is 44.29 and 303.7% above the Healthcare Providers & Services industry median of 10.97. LifeStance Health Group's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current EV-to-EBITDA is 44.29 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeStance Health Group (LFST) Overvalued in 2026?
Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued.
The current stock price of $10.71 is trading 30.1% above its estimated GF Value™ of $8.23.
GuruFocus considers LifeStance Health Group to be Significantly Overvalued.
Key valuation signals for LFST:
EV-to-EBITDA: 44.29
GF Value™: $8.23 vs. price of $10.71 (30.1% above fair value)
Industry Position: 303.7% above the Healthcare Providers & Services median (#449 of 505)
No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
56GF Score
Get the complete analysis for LFST
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFST has been successfully added to your 
